Em Vigor, page-40

First 40 Last

Share
Profile

Follow
wombat777

2,175 Posts.

282

26/03/18

09:18

Post #: 32016259
Share

Originally posted by Verminski ↑

VANADIUM METALLURGICAL TESTWORK
During April 2014, Syrah engaged Chalieco, the international engineering arm of the Chinalco Group, to complete the Vanadium Scoping Study. Chalieco was selected by Syrah based on its experience in undertaking the engineering work on eight vanadium projects in China with a similar ore assemblage to that of Balama (vanadium hosted in graphitic schists). In China, the vanadium is hosted in amorphous graphite (and not flake like Balama).
On 8 April 2014, Syrah announced that metallurgical testwork to date has shown that the vanadium reports to the tailings during the graphite flotation process. Assays on the graphite concentrate show that vanadium is below detection limits in the graphite concentrate.
Magnetic rich mineralisation (mainly magnetite and limonite) can be upgraded by 8-11 times to achieve a V2O5 grade of 4-5% by a WHIMS (Wet high Intensity Magnetic Separator). Non-magnetic mineralisation (mainly roscoelite) can be upgraded by 4-5 times to achieve a V2O5 grade of 2-2.5% by flotation. These two processes have been demonstrated to produce a combined concentrate grade of >3% V2O5. The Vanadium Scoping Study has conservatively assumed a combined concentrate grade of 2.5% V2O5.
Chemical processing of this initial vanadium concentrate had shown that a 98.5% purity vanadium pentoxide can be produced.

So two methods, seems Syrah are to ramp up Vanadium when the Graphite becomes a bit more steady state. Also they have produced samples from Balama of 99%+ which is apparently hard to achieve from the Graphite recovered in China. As we are attached to the same resource one could plausibly assume BAT can also achieve that level of recovery. Montepuez? Looking at type of flake in relation to Balama you could probably ditto that.

Expand

Just noticed that vanadium resource is identified in resource statements in latest investment preso.

Could not see any detailed coverage of it in the studies. Often this sort of thing is treated as an opex credit. Does anyone know if there is much change needed to the process plant to address recovery?

BAT Price at posting: 7.4¢ Sentiment: Buy Disclosure: Held
4 Upvote

0 Great analysis

Reply

Top Stories

IMR

Imricor Med and Philips launch commercial iMR lab solution

TGN

Tungsten has soared +700% YTD, the US is curbing its exports, and this ASX stock is targeting production in Q1CY27

HotCopper Highlights Week 35: X2M, AnteoTech and Brighstar dominate forum chatter

MEM

Memphasys receives early Thai FDA Felix approval

NVA

Nova Minerals achieves key milestone on path to Alaskan antimony production

SEN

Senetas experiences stronger cash flow as revenue rises, flags FY27 sales pipeline

AS2

Capital Compass: Askari Metals advances Ethiopia strategy as permitting remains key focus

D3E

D3 Energy detects gas in South African helium hunt well

CVL

Civmec earnings: Profit climbs as $1.4b order book backs FY27 growth

4DX

4DMedical posts FY26 revenue growth as commercial deployment ramps up

First 40 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

Em Vigor, page-40

Top Stories

Imricor Med and Philips launch commercial iMR lab solution

Tungsten has soared +700% YTD, the US is curbing its exports, and this ASX stock is targeting production in Q1CY27

HotCopper Highlights Week 35: X2M, AnteoTech and Brighstar dominate forum chatter

Memphasys receives early Thai FDA Felix approval

Nova Minerals achieves key milestone on path to Alaskan antimony production

Senetas experiences stronger cash flow as revenue rises, flags FY27 sales pipeline

Capital Compass: Askari Metals advances Ethiopia strategy as permitting remains key focus

D3 Energy detects gas in South African helium hunt well

Civmec earnings: Profit climbs as $1.4b order book backs FY27 growth

4DMedical posts FY26 revenue growth as commercial deployment ramps up

Featured News